Impact of encorafenib on survival of patients with BRAF
BRAFV600E
Chemotherapy
Encorafenib
Metastatic colorectal cancer
Journal
Journal of cancer research and clinical oncology
ISSN: 1432-1335
Titre abrégé: J Cancer Res Clin Oncol
Pays: Germany
ID NLM: 7902060
Informations de publication
Date de publication:
Nov 2023
Nov 2023
Historique:
received:
05
07
2023
accepted:
06
07
2023
pubmed:
19
7
2023
medline:
19
7
2023
entrez:
19
7
2023
Statut:
ppublish
Résumé
Patients with BRAF Clinico-pathological data were extracted from the electronic health records. Kaplan-Meier method was used to estimate overall (OS) and progression-free survival (PFS). Objective response rate (ORR) was assessed according to RECIST 1.1. In total, 51 patients were enrolled. FOLFOXIRI was administered to 12 patients; 29 patients received FOLFOX or FOLFIRI as first-line treatment. Median OS was 17.6 months. Median PFS with FOLFOXIRI (13.0 months) was significantly prolonged (HR 0.325) as compared to FOLFOX/FOLFIRI (4.3 months). However, this failed to translate into an OS benefit (p = 0.433). Interestingly, addition of a monoclonal antibody to chemotherapy associated with superior OS (HR 0.523). A total of 64.7% patients received further-line therapy, which included a BRAF inhibitor in 17 patients. Targeted therapy associated with very favourable OS (25.1 months). Patients with BRAF
Identifiants
pubmed: 37466791
doi: 10.1007/s00432-023-05141-y
pii: 10.1007/s00432-023-05141-y
pmc: PMC10587317
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
12903-12912Informations de copyright
© 2023. The Author(s).
Références
Colorectal Dis. 2013 Dec;15(12):e711-8
pubmed: 24112392
Br J Cancer. 2009 Aug 4;101(3):465-72
pubmed: 19603024
J Clin Oncol. 2017 Aug 10;35(23):2624-2630
pubmed: 28486044
Eur J Cancer. 2017 Jul;79:50-60
pubmed: 28463756
Eur J Cancer. 2015 Mar;51(5):587-94
pubmed: 25673558
J Clin Oncol. 2020 Aug 20;:JCO2001225
pubmed: 32816630
J Natl Compr Canc Netw. 2021 Mar 02;19(3):329-359
pubmed: 33724754
Lancet Oncol. 2015 Oct;16(13):1306-15
pubmed: 26338525
N Engl J Med. 2019 Oct 24;381(17):1632-1643
pubmed: 31566309
Gut. 2012 Jun;61(6):847-54
pubmed: 22427238
J Clin Oncol. 2010 Jan 20;28(3):466-74
pubmed: 20008640
J Cancer. 2019 May 26;10(10):2332-2341
pubmed: 31258736
Ann Oncol. 2016 Aug;27(8):1386-422
pubmed: 27380959
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Br J Cancer. 2015 Jun 9;112(12):1888-94
pubmed: 25989278
JAMA. 2017 Jun 20;317(23):2392-2401
pubmed: 28632865
Br J Cancer. 2016 Jan 12;114(1):30-6
pubmed: 26575603
Ann Oncol. 2017 Aug 01;28(8):1713-1729
pubmed: 28407110
Carcinogenesis. 2004 Apr;25(4):527-33
pubmed: 14688025
Br J Cancer. 2011 Mar 1;104(5):856-62
pubmed: 21285991
Gastroenterology. 2015 Jan;148(1):88-99
pubmed: 25305506
Ann Oncol. 2016 Sep;27(9):1746-53
pubmed: 27358379
Ann Oncol. 2019 Jan 1;30(1):124-131
pubmed: 30339194